# Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

> **NCT04056975** · PHASE1 · UNKNOWN · sponsor: **EVIVE Biotechnology** · enrollment: 54 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Recombinant Anti-CD19m-CD3 Antibody Injection

## Key facts

- **NCT ID:** NCT04056975
- **Lead sponsor:** EVIVE Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-15
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-01-27
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056975, "Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04056975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*